Table 1.
Baseline characteristics of included studies, n (%)
| Ref. | Study design | Follow-up duration | Stent type |
Sample size
|
Age (years), mean (SD)
|
Gender (male)
|
Left ventricular ejection fraction (%), mean (SD)
|
Current smoking
|
Diabetes mellitus
|
Hypertension
|
Prior myocardial infarction
|
||||||||
|
OCT-PCI
|
Angio-PCI
|
OCT-PCI
|
Angio-PCI
|
OCT-PCI
|
Angio-PCI
|
OCT-PCI
|
Angio-PCI
|
OCT-PCI
|
Angio-PCI
|
OCT-PCI
|
Angio-PCI
|
OCT-PCI
|
Angio-PCI
|
OCT-PCI
|
Angio-PCI
|
||||
| CALIPSO, 2025, Amabile et al[15] | RCT | 1 month | DES (everolimus) | 65 | 69 | 71.17 (8.72) | 73.83 (7.95) | 52 (80) | 57 (83) | 58.33 (11.37) | 58 (10.60) | 8 (12) | 10 (15) | 24 (37) | 27 (39) | 46 (71) | 43 (62) | - | - |
| LUMIEN IV Sub-study, 2024, Ali et al[11] | RCT, Sub-analysis | 24 months | DES (everolimus) | 992 | 981 | 65.6 (10.5) | 65.7 (10.4) | 792 (79.8) | 750 (76.5) | 55.1 (8.5) | 55.1 (8.5) | 198 (20) | 192 (19.6) | 360 (36.3) | 342 (34.9) | 707 (71.3) | 734 (74.8) | 211 (21.3) | 255 (26.0) |
| OCCUPI, 2024, Hong et al[14] | RCT | 12 months | DES (everolimus) | 803 | 801 | 63.67 (9.65) | 64.0 (8.91) | 646 (80) | 644 (80) | 59.5 (8.8) | 59.5 (8.8) | 149 (19) | 158 (20) | 261 (33) | 262 (33) | 466 (58) | 451 (56) | 40 (5) | 42 (5) |
| OCTOBER, 2023, Holm et al[12] | RCT | 24 months | DES (everolimus) | 600 | 601 | 66.4 (10.5) | 66.2 (9.9) | 473 (78.8) | 475 (79.0) | 56.50 (7.43) | 56.50 (7.43) | 77 (12.8) | 85 (14.1) | 103 (17.2) | 97 (16.1) | 422 (70.3) | 448 (74.5) | 170 (28.3) | 180 (30.0) |
| RENOVATE-COMPLEX-PCI, 2024, Lee et al[13] | RCT, Sub-analysis | 25.2 months | DES (everolimus) | 278 | 547 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Detailed baseline characteristics for the RENOVATE-COMPLEX PCI, 2024 were not detailed for the optical coherence tomography-guided percutaneous coronary intervention (PCI) subgroup within the intravascular ultrasound guided PCI. Angio-PCI: Angiography-guided percutaneous coronary intervention; DES: Drug-eluting stent; OCT-PCI: Optical coherence tomography-guided percutaneous coronary intervention; RCT: Randomized controlled trial.